ProfileGDS4814 / ILMN_2258409
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 1% 4% 4% 3% 23% 39% 10% 13% 6% 6% 2% 23% 2% 27% 29% 11% 2% 2% 1% 2% 2% 1% 11% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)36.15661
GSM780708Untreated after 4 days (C2_1)38.85734
GSM780709Untreated after 4 days (C3_1)39.15764
GSM780719Untreated after 4 days (C1_2)38.4263
GSM780720Untreated after 4 days (C2_2)44.211123
GSM780721Untreated after 4 days (C3_2)47.410639
GSM780710Trastuzumab treated after 4 days (T1_1)41.060910
GSM780711Trastuzumab treated after 4 days (T2_1)42.050813
GSM780712Trastuzumab treated after 4 days (T3_1)39.87856
GSM780722Trastuzumab treated after 4 days (T1_2)39.81896
GSM780723Trastuzumab treated after 4 days (T2_2)37.44422
GSM780724Trastuzumab treated after 4 days (T3_2)44.163923
GSM780713Pertuzumab treated after 4 days (P1_1)37.45232
GSM780714Pertuzumab treated after 4 days (P2_1)44.927
GSM780715Pertuzumab treated after 4 days (P3_1)45.385129
GSM780725Pertuzumab treated after 4 days (P1_2)41.463911
GSM780726Pertuzumab treated after 4 days (P2_2)37.5682
GSM780727Pertuzumab treated after 4 days (P3_2)37.73912
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)34.51141
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)37.53492
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)37.70522
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)36.22311
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)41.333711